Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

TerminatedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

March 15, 2016

Primary Completion Date

December 19, 2016

Study Completion Date

December 19, 2016

Conditions
Neuroblastoma
Interventions
DRUG

Dinutuximab

Unituxin was administered along with cytokines according to the prescribing information

Trial Locations (18)

10032

Columbia University Medical Center, New York

17033

Penn State Hershey Children's Hospital, Hershey

27710

Duke University Medical Center, Durham

28203

Carolinas Medical Center / Levine Children's Hospital, Charlotte

35233

University Of Alabama At Birmingham, Birmingham

37232

Vanderbilt-Ingram Cancer Center, Nashville

43205

Nationwide Children's Hospital, Columbus

48109

University of Michigan - C S Mott Children's Hospital, Ann Arbor

55404

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis

60637

University of Chicago, Chicago

64108

Children's Mercy Hospital, Kansas City

72202

Arkansas Children's Hospital, Little Rock

76104

Cook Children's Health Care System, Fort Worth

90027

Children's Hospital Los Angeles, Los Angeles

92123

Rady Children's Hospital- San Diego, San Diego

92868

Children's Hospital of Orange County, Orange

98105

Seattle Children's Hospital, Seattle

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

United Therapeutics

INDUSTRY

NCT02693171 - Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients | Biotech Hunter | Biotech Hunter